According to FutureWise analysis the market for HLA Typing in 2023 is US$ 1.49 billion, and is expected to reach US$ 2.51 billion by 2031 at a CAGR of 6.72%.
Increased insistence for diagnostic products, increased private-public collaboration for extensive HLA research, rising prevalence of infectious diseases and soaring number of transplant processes are some of the crucial factors responsible for the growth of the market. HLA class I and II antigen identification is performed by the procedure of molecular diagnostics that is based on DNA. These novel innovations of the DNA are being utilised by the HLA typing that provide more accurate, vigorous results that rely on identifying the differences in HLA genes. Furthermore, advancements in technology, rise in the number of processes that involve stem cell transplantation, soft tissue transplantation and solid organ transplantation, bolstering support in R and D, escalating public and private funds are some of the other driving factors responsible for the HLA typing market growth. Additionally, the technological shift to gene-based HLA profiling from serological assays shall boost the proliferation of the market.